Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
BMJ Support Palliat Care ; 13(e2): e476-e483, 2023 Dec 07.
Artículo en Inglés | MEDLINE | ID: mdl-34470770

RESUMEN

OBJECTIVES: Identifying the prevalence of palliative care (PC) needs among patients who die at the emergency department (ED) and to assess symptom control and aggressiveness of care. METHODS: We conducted a decedent cohort study of adults deceased at the ED of a Portuguese teaching hospital in 2016. PC needs were identified using the National Hospice Organization terminality criteria and comorbidities measurement by the Charlson's Index. RESULTS: 384 adults died at the ED (median age 82 (IQR 72-89) years) and 78.4% (95% CI 73.9% to 82.2%) presented PC needs. Only 3.0% (n=9) were referred to the hospital PC team. 64.5%, 38.9% and 57.5% experienced dyspnoea, pain and confusion, respectively. Dyspnoea was commonly medicated (92%), against 56% for pain and 8% for confusion. Only 6.3% of the patients were spared from aggressive interventions, namely blood collection (86.0%) or intravenous fluid therapy (63.5%). The burden of aggressive interventions was similar between those with or without withhold cardiopulmonary resuscitation order (median 3 (2-4) vs 3 (2-5)), p=0.082. CONCLUSIONS: Nearly four out of five adults who died at the ED had PC needs at the time of admission. Most experienced poor symptom control and care aggressiveness in their last hours of life and were mostly unknown to the PC team. The findings urge improvements in the care provided to patients with PC needs at the ED, focusing on patient well-being and increased PC referral.


Asunto(s)
Hospitales para Enfermos Terminales , Medicina Paliativa , Adulto , Humanos , Anciano de 80 o más Años , Estudios de Cohortes , Cuidados Paliativos , Servicio de Urgencia en Hospital , Dolor , Disnea/terapia
2.
Biochim Biophys Acta ; 1813(3): 492-9, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21223980

RESUMEN

In order to investigate the cell death-inducing effects of rotenone, a plant extract commonly used as a mitochondrial complex I inhibitor, we studied cancer cell lines with different genetic backgrounds. Rotenone inhibits cell growth through the induction of cell death and cell cycle arrest, associated with the development of mitotic catastrophe. The cell death inducer staurosporine potentiates the inhibition of cell growth by rotenone in a dose-dependent synergistic manner. The tumor suppressor p53 is involved in rotenone-induced cell death, since the drug treatment results in increased expression, phosphorylation and nuclear localization of the protein. The evaluation of the effects of rotenone on a p53-deficient cell line revealed that although not required for the promotion of mitotic catastrophe, functional p53 appears to be essential for the extensive cell death that occurs afterwards. Our results suggest that mitotic slippage also occurs subsequently to the rotenone-induced mitotic arrest and cells treated with the drug for a longer period become senescent. Treatment of mtDNA-depleted cells with rotenone induces cell death and cell cycle arrest as in cells containing wild-type mtDNA, but not formation of reactive oxygen species. This suggests that the effects of rotenone are not dependent from the production of reactive oxygen species. This work highlights the multiple effects of rotenone in cancer cells related to its action as an anti-mitotic drug.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Ciclo Celular/efectos de los fármacos , Mitosis/efectos de los fármacos , Rotenona/farmacología , Proteína p53 Supresora de Tumor/metabolismo , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Senescencia Celular/efectos de los fármacos , Sinergismo Farmacológico , Inhibidores Enzimáticos/farmacología , Fabaceae/química , Humanos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Estaurosporina/farmacología , Neoplasias de la Tiroides/tratamiento farmacológico , Desacopladores/farmacología
3.
Front Plant Sci ; 11: 599, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32547572

RESUMEN

Efforts to boost crop yield and meet global food demands while striving to reach sustainability goals are hindered by the increasingly severe impacts of abiotic stress, such as drought. One strategy for alleviating drought stress in crops is to utilize root-associated bacteria, yet knowledge concerning the relationship between plant hosts and their microbiomes during drought remain under-studied. One broad pattern that has recently been reported in a variety of monocot and dicot species from both native and agricultural environments, is the enrichment of Actinobacteria within the drought-stressed root microbiome. In order to better understand the causes of this phenomenon, we performed a series of experiments in millet plants to explore the roles of drought severity, drought localization, and root development in provoking Actinobacteria enrichment within the root endosphere. Through 16S rRNA amplicon-based sequencing, we demonstrate that the degree of drought is correlated with levels of Actinobacterial enrichment in four species of millet. Additionally, we demonstrate that the observed drought-induced enrichment of Actinobacteria occurs along the length of the root, but the response is localized to portions of the root experiencing drought. Finally, we demonstrate that Actinobacteria are depleted in the dead root tissue of Japanese millet, suggesting saprophytic activity is not the main cause of observed shifts in drought-treated root microbiome structure. Collectively, these results help narrow the list of potential causes of drought-induced Actinobacterial enrichment in plant roots by showing that enrichment is dependent upon localized drought responses but not root developmental stage or root death.

4.
Sci Rep ; 6: 29714, 2016 07 14.
Artículo en Inglés | MEDLINE | ID: mdl-27411289

RESUMEN

One of the hallmarks of cancer is its unlimited replicative potential that needs a compensatory mechanism for the consequential telomere erosion. Telomerase promoter (TERTp) mutations were recently reported as a novel mechanism for telomerase re-activation/expression in order to maintain telomere length. Pancreatic endocrine tumors (PETs) were so far recognized to rely mainly on the alternative lengthening of telomeres (ALT) mechanism. It was our objective to study if TERTp mutations were present in pancreatic endocrine tumors (PET) and could represent an alternative mechanism to ALT. TERTp mutations were detected in 7% of the cases studied and were mainly associated to patients harbouring hereditary syndromes. In vitro, using PET-derived cell lines and by luciferase reporter assay, these mutations confer a 2 to 4-fold increase in telomerase transcription activity. These novel alterations are able to recruit ETS transcription factor members, in particular GABP-α and ETV1, to the newly generated binding sites. We report for the first time TERTp mutations in PETs and PET-derived cell lines. Additionally, our data indicate that these mutations serve as an alternative mechanism and in an exclusive manner to ALT, in particular in patients with hereditary syndromes.


Asunto(s)
Mutación , Neoplasias Pancreáticas/genética , Regiones Promotoras Genéticas/genética , Telomerasa/genética , Adolescente , Adulto , Anciano , Línea Celular Tumoral , Femenino , Regulación Neoplásica de la Expresión Génica , Enfermedades Genéticas Congénitas/genética , Enfermedades Genéticas Congénitas/metabolismo , Enfermedades Genéticas Congénitas/patología , Humanos , Hibridación Fluorescente in Situ , Masculino , Persona de Mediana Edad , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patología , Síndrome , Telomerasa/metabolismo , Telómero/enzimología , Telómero/genética , Homeostasis del Telómero/genética , Adulto Joven
5.
Life Sci ; 89(11-12): 371-7, 2011 Sep 12.
Artículo en Inglés | MEDLINE | ID: mdl-21807000

RESUMEN

AIMS: Oncogenic RET/PTC1 chromosomal rearrangements are hallmarks of thyroid papillary carcinoma. The resulting protein, mainly through tyrosine 451, is responsible for the activation of pathways controlling cell survival, including the PI3K/Akt/mTOR cascade. Vanadium compounds were shown to have anti-neoplastic potential. However, reports about their mechanism of action are contradictory, particularly in what concerns the signaling mediators that are involved. Here, the aim was to characterize the effects of orthovanadate in thyroid cancer cells harboring RET/PTC1. MAIN METHODS: Growth behavior of orthovanadate-treated cells was evaluated by the sulphorhodamine B assay, cell cycle analysis and Terminal Transferase dUTP Nick End Labeling (TUNEL). Mitochondrial parameters such as the transmembrane potential and production of reactive oxygen species (ROS) were also assessed. Western blot was used to study cellular signaling. KEY FINDINGS: Low doses of the compound induce a pro-proliferative response. In contrast, treatment with inhibitory concentrations of orthovanadate results in increased phosphorylation of tyrosine 451 of RET/PTC1 and activation of the mTOR/S6R branch of the PI3K/Akt signaling pathway. These concentrations of the drug also induce typical features of apoptosis including DNA fragmentation, loss of mitochondrial membrane potential, production of ROS and activation of caspase-3. Addition of the glial cell line-derived neutrophic factor, a pro-survival stimulator that acts through RET, could not completely block orthovanadate-induced growth inhibition and cell death. SIGNIFICANCE: In this model, orthovanadate induces caspase-dependent apoptosis and interferes with the PI3K/Akt/mTOR cascade. This work provides characterization of the effects of orthovanadate and underlines the possibility of its usefulness as a cell death modulator.


Asunto(s)
Antineoplásicos/farmacología , Apoptosis , Caspasas/metabolismo , Proteínas de Fusión Oncogénica/metabolismo , Proteínas Tirosina Quinasas/metabolismo , Neoplasias de la Tiroides/patología , Vanadatos/farmacología , Antineoplásicos/toxicidad , Carcinoma , Carcinoma Papilar , Proliferación Celular/efectos de los fármacos , Activación Enzimática , Factor Neurotrófico Derivado de la Línea Celular Glial/metabolismo , Humanos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Proteína Oncogénica v-akt/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Fosforilación , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Especies Reactivas de Oxígeno/metabolismo , Transducción de Señal , Serina-Treonina Quinasas TOR/metabolismo , Cáncer Papilar Tiroideo , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/metabolismo , Células Tumorales Cultivadas , Vanadatos/toxicidad
6.
J Biosci ; 36(4): 639-48, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21857110

RESUMEN

TPC-1 is a highly proliferative thyroid papillary carcinoma-derived cell line. These cells express the RET/PTC1 fusion protein, whose isoforms are characterized in this work. The bacterial alkaloid staurosporine and the plant extract rotenone are death-inducing drugs that have an inhibitory synergistic effect on the growth of TPC-1 cells. We show that this synergism is accompanied by an enhancement of the induction of cell death. Staurosporine alone induces cell cycle arrest in G1, whereas rotenone induces arrest in G2/M. We suggest that this additive pressure may drive cells to die, resulting in the synergistic interaction of the drug combination. These data emphasize the potential use of the staurosporine plus rotenone combination as an anticancer tool.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Carcinoma Papilar/tratamiento farmacológico , Muerte Celular/efectos de los fármacos , Proteínas de Fusión Oncogénica , Proteínas Proto-Oncogénicas c-ret/genética , Receptores de Superficie Celular/genética , Rotenona/farmacología , Estaurosporina/farmacología , Neoplasias de la Tiroides/tratamiento farmacológico , Western Blotting , Carcinoma , Carcinoma Papilar/genética , Carcinoma Papilar/metabolismo , Puntos de Control del Ciclo Celular/efectos de los fármacos , Puntos de Control del Ciclo Celular/genética , Muerte Celular/genética , División Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Sinergismo Farmacológico , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Humanos , Proteínas de Fusión Oncogénica/genética , Proteínas de Fusión Oncogénica/metabolismo , Receptores Patched , Proteínas Proto-Oncogénicas c-ret/metabolismo , Receptores de Superficie Celular/metabolismo , Cáncer Papilar Tiroideo , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/metabolismo , Glándula Tiroides/patología , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA